Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
With
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed melanoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
Prior chemotherapy, immunotherapy, radiation therapy (Phase I portion only), cytokine, biologic, or vaccine therapy is permitted, however no prior treatment with temozolomide
Measurable disease
Performance status \<= 2
Life expectancy greater than 3 months
You may not be if
No prior treatment with temozolomide or imatinib mesylate
Organ allografts
Prior radiotherapy, or prior intratumor injection therapy, to areas of measurable disease that are used as target indicator lesions, unless progression has occurred at that site or measurable disease has developed outside the treatment area
Pregnancy or lactation
History of second cancer
Known hypersensitivity to temozolomide or imatinib
Use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment
Clareo Health | Study of Temzolomide and Gleevec in Advanced Melanoma
